Clinical TrialMay 12, 2026, 10:17 PM
Ascentage Pharma to Present 17 Clinical Advances at EHA2026
AI Summary
Ascentage Pharma Group International announced that 17 clinical advances of its core assets, Olverembatinib and Lisaftoclax, will be featured at the 31st Congress of the European Hematology Association (EHA2026). These include 8 poster presentations showcasing updated efficacy and safety data from ongoing clinical studies. The EHA2026 Congress is scheduled to convene in Stockholm, Sweden, from June 11 to 14, 2026.
Key Highlights
- Ascentage Pharma to feature 17 clinical advances at the 31st Congress of the European Hematology Association (EHA2026).
- The presentations include 8 poster presentations.
- Data will be presented for Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor.
- Data will also be presented for Lisaftoclax (APG-2575), China-developed Bcl-2 selective inhibitor.
- EHA2026 Congress will take place in Stockholm, Sweden, from June 11 to 14, 2026.
- Key abstracts include updated efficacy and safety of Olverembatinib as second-line therapy in CP-CML.
- Another abstract covers the efficacy of Olverembatinib in CP-CML patients with prior resistance to ponatinib or asciminib and ASXL1 mutations.
- Updated results of POLARIS-1 Phase 3 study for Olverembatinib combined with low-intensity chemotherapy in newly diagnosed Ph+ ALL will be presented.
Price Impact
More from AAPG